Your Trusted Science-backed Resource for Health, Nutrition, Beauty, and Lifestyle since 2012
Australian professor Thomas Borody who advocated Covid-19 therapy including ivermectin applied for patent
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
ASydneygastroenterologist who has been enthusiastically promoting an unapproved Covid-19 treatment, including to Australian politicians and general practitioners, has filed a patent in the US for the same treatment, allowing him to commercialise and profit from it, if approved.
The protocol involves a combination of the anti-parasitic drug ivermectin, zinc and the antibiotic doxycycline.
In December 2020 Borody filed a patent in the US for therapeutic combinations of drugs, including a combination of ivermectin, an antibiotic and zinc. Patenting a treatment means the owner of the patent is allowed to exclusively manufacture, market and profit from the drug until the patent expires, usually after 20 years.
Borody did not declare in numerous media interviews, or in his appeals to state and federal governments for funding and adoption of the treatment, that he also sought to potentially profit from it. While this is not illegal or in breach of professional regulations, medical and research experts Guardian Australia spoke to expressed concern that it may be unethical and a conflict of interest.
In a statement to the Guardian sent via lawyers, Borody denied any wrongdoing and said: “My client has never hidden the fact that he applied for patents over his -19 treatment. That is a matter of public record for some time now.”
On 23 August 2020, four months before filing the patent, Borody wrote to the Australian health minister, Greg Hunt, requesting funding for the therapy. Hunt responded that Borody should apply for funding through independent processes to study the ivermectin treatment as part of a clinical trial.
When asked if Borody had declared his intentions to patent the therapy, or made them aware once it was filed, a spokesperson for Hunt told Guardian Australia: “We are not aware of Prof Borody’s private interests and to the best of our knowledge have no record of having received any such declaration.”
Borody has been lobbying the federal government for more than a year to support the treatment, both before and after the filing of the patent.
The former Liberal MP and now leader of the United Australia party, Craig Kelly, has promoted Borody and the treatment on Twitter, and in February urged the national Covid evidence taskforce, which sets guidelines for clinicians, to “please look at the evidence” for the treatment, citing Borody’s work. It is not clear whether Kelly was aware of the patent application at the time.
On Twitter, Kelly has claimed government and pharmaceutical companies refuse to endorse ivermectin as a treatment because it is not profitable, given that it is a drug that has long existed and is cheap to produce. “The moment that Big Govt accepts cheap & accessible Ivermectin can be effective & would set us free quickly, it would stop Big Pharma making BIG $$$ Big Pharma JUST playing us for $$$,” Kelly wrote on Twitter on 11 July.
Kelly told Guardian Australia in a statement: “I have no problems with people like Prof Borody seeking to protect their intellectual property when they discover a new treatment, as do the big pharmaceutical companies who aggressively protect their intellectual property, even to the extent of denying access to developing countries.
“I first spoke to Professor Borody in May of last year … And I’m aware that he has invested a substantial sum of his own money to undertake trials and develop the intellectual property.”
Lobbying the government
In July this year Borody emailed a doctor who was also lobbying the government and attached his triple-drug “treatment protocol to control Covid-19 in NSW in conjunction with vaccination”. Borody suggested the treatment could “curb the current outbreak rapidly”.
“This can be rolled out across Australia not just NSW,” he wrote. He also attached a pre-print scientific paper that he claimed showed the efficacy of the protocol and a “near 100% cure” rate in 24 patients.
“Thank you for bringing this to the Minister,” Borody wrote to the doctor. “This approach adds a badly needed ANTIVIRAL TREATMENT to the VACCINE …. to stop the outbreak, [and] abolish all lockdowns. A zoom explanation for further details and plans would most likely be of help to a Ministerial assistant.”
But another study co-authored by Borody and published in August this year, titled “Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19”, does make clear that Borody is “a principal in Topelia Therapeutics (Ventura, California), which seeks to commercialize cost-effective treatments for COVID-19, including IVM [ivermectin]”. A “competing interest statement” in another study, a pre-print published in July, entitled “Effectiveness of Ivermectin-Based Multidrug Therapy in Severe Hypoxic Ambulatory COVID-19 Patients”, also states that Borody and another author have “patents relevant to the study”.
In August 2020 Borody’s Centre For Digestive Diseases issued a press release promoting the triple treatment, encouraging GPs to prescribe the drugs “off label”. Off-label prescribing, which is legal, is when a doctor prescribes a drug to treat a condition it is not indicated for by the manufacturer or approved to treat by drug regulators.
The press release again does not refer to any intention by Borody to file a patent for and profit from the same treatment.
The Therapeutic Goods Administration investigated Borody over his centre’s advertising of a prescription medicine as part of its promotion of the treatment protocol.
“The TGA investigated Prof Borody and the Centre for Digestive Diseases’ alleged advertising of a triple-therapy protocol for treating Covid-19 in mid to late 2020,” a spokesperson said. “The advertising compliance investigation was closed following removal of relevant content that promoted the use of the protocol, including a prescription medicine, from the website. Prescription medicines cannot be advertised in Australia unless a permission applies.”
The TGA was forced to change its prescribing rules for ivermectin in September this year due to concerns GPs were prescribing it to patients for the prevention or treatment of Covid-19 despite it not being approved for such use in Australia. There have been reports of poisonings among patients taking higher than recommended doses of the drug in a bid to combat Covid-19.
The National Covid-19 Clinical Evidence Taskforce, the body which makes official recommendations to doctors about how to treat the virus, advises in its clinical treatment guidelines not to use ivermectin for the treatment of Covid-19 outside randomised trials with appropriate ethical approval.
Australia’s Therapeutic Goods Administration changed its prescribing rules for ivermectin due to concerns it was being used to treat Covid despite not being approved for that. Photograph: Cultura Creative (RF)/Alamy Prof Tari Turner, the director of evidence and methods at the taskforce, said: “When claims are made about the effectiveness of treatments, it is vital that any potential conflicts of interest are declared.
“This applies to panel members making guidelines, recommendations, and people designing and conducting research, and also to clinicians advocating treatments.
“These declarations need to be specific enough for others to be able to evaluate the extent to which any conflicts of interest might impact on the statements or claims those people are making.”
There are serious concerns about many studies by other researchers published to date that claim to show ivermectin is an effective Covid-19 treatment either alone or in combination with other drugs. Many of the studies have been criticised for serious flaws in their design and recruitment of patients, and have been shown to be unreliable. There are no strong studies with large numbers of patients published in peer-reviewed medical journals that show ivermectin alone or in combination with other drugs is an effective preventative against or treatment for Covid-19, though these trials are under way. Most studies to date have been too small to be clinically significant, or poorly designed.
Borody told the Guardian in a statement from his lawyer that he holds 162 patents for different treatments and therapies for various diseases. He referred to his previous work in the 1980s developing the first therapy, also a combination therapy, to fight H pylori and cure peptic ulcers. This went on to become the gold standard treatment for peptic ulcers globally.
“As a practising doctor and medical specialist, I have been at the forefront of medical research for more than 40 years focusing primarily on repurposing safe, effective, cheap and approved therapies resulting in FDA [US Food and Drug Administration] and TGA approved triple therapies,” Borody said in the statement.
“This includes the life-saving triple therapy for peptic ulcers with a track record of having saved millions of lives worldwide and 1,050 lives each year in Australia, as well as more than $10bn in hospitalisation costs.
“That would not have been possible unless the therapy had been patented.”
Assoc Prof Wendy Lipworth, from the University of Sydney’s Health Ethics centre, said: “There’s nothing wrong with applying for a patent.
“But declaring that patent, when you are becoming a public figure for promoting a treatment, is the bare minimum of your ethical obligations …
“As a medical professional, there is an obligation to appraise the evidence subjectively and give advice without bias. I think that’s where the tension is.
“There’s nothing wrong even with having a conflict of interest. What really is the issue is how it is managed, and the most important issue is not declaring it.”
She added: “Part of due diligence at the very least should be to have a declaration at the bottom about conflicts of interests to do with that treatment. To not do that is blatantly unethical.”
The benefit of applying for a patent in the US is it is a signatory to the international patent cooperation treaty, which means by applying in the US, applicants can simultaneously seek protection for an invention in a large number of countries.
The patent expert and principal of Stephens Lawyers, Katarina Klaric, said: “Once a patent is granted, the patent owner has a monopoly in respect of the invention, that is the exclusive commercial rights to exploit the invention the subject of the patent.
“This means that the patent owner can take legal action to stop others from manufacturing, marketing, distributing, selling or otherwise commercially exploiting the invention.”
There are considerable commercial benefits in having a patent because of the monopoly rights granted, she said.
“Monopoly rights enable patent owners to recoup some of the substantial investment made in research and development and clinical trial to get a drug to market.” Conflict of interest questions
On Wednesday, six days after Guardian Australia issued Borody with a series of questions asking about the patent and the extent to which he had declared the apparent conflict of interest, Topelia Australia issued a press release – months after the patent was filed – announcing it had “secured exclusive global patent rights to Covid-19 Antiviral Triple Therapy from Prof Thomas Borody”. The treatment, trademarked as Ziverdox, is a combination therapy including zinc, ivermectin and doxycycline.
Through his lawyer, Borody said although Covid-19 treatment patents had been filed under Borody’s name, those applications and the patents once granted are owned by Topelia Australia.
“There is no guarantee that Topelia will make any money from its patents such is the nature of the commercialisation and development of new pharmaceutical drugs, as well as the pharmaceutical industry,” Borody’s lawyer said.
An Australian Securities and Investments Commission search shows Borody is both the director and secretary of Topelia Australia. The address listed is the Centre for Digestive Diseases. According to the Topelia Australia press release issued this week, the company is hoping to raise $25m from investors in its bid to gain TGA approval, conduct clinical trials and eventually commercialise the treatment.
The president of the Australian Medical Association, Dr Omar Khorshid, said Borody should declare the relevant patent when promoting his Covid-19 triple therapy. “Any doctor who is advocating to government or to a regulator for approval of a new treatment would of course have to declare their interest in that,” he said.
“It is a direct conflict of interest. The extent of your conflict has to be declared, not just that there is one, but you have to declare how big it is. Is it a financial one? Are you being paid? Do you have a commercial relationship, do your family members have one?
“And I think we have an obligation also to disclose to our individual patients if we have some kind of financial interest in our treatment that we’re providing or promoting. That’s all part of normal business as usual for the medical profession.”
In a statement to the Guardian sent via lawyers, Borody denied that he had “done anything wrong or illegal when advocating for the repurposing of existing medicines to treat Covid-19”.
“My client has never hidden the fact that he applied for patents over his Covid-19 treatment. That is a matter of public record for some time now. It is self-evident that if a prolific inventor, such as Dr Borody, is advocating the use of his Covid-19 treatment, then he is likely to have a financial interest in that treatment.
“He is a responsible doctor who holds himself to the highest standards in medical practice and research. He is a strong believer in fairness and equity. He is not afraid to challenge medical orthodoxy based on his evidence-based medical research.
“It is silly to allege that my client has an obligation to disclose his financial interest in his treatment when dealing with the federal health minister, members of parliament and others, [or in media appearances and interviews] when he is approaching them on the basis that: (a) he is a medical specialist who has invented his own Covid-19 treatment based on repurposed existing medicines; and (b) his reputation as a medical inventor speaks for itself …
“He shared his Covid-19 therapy for free with other Australian general practitioners who requested it. It was not illegal then, and it is not illegal now, for my client to have shared his protocol with Australian general practitioners who wanted it.”
Ivermectin Resources Recently, I have seen tremendous demand for some sort of initial guidance “WHERE TO START” with High Dose Ivermectin for CANCER. I have two articles and a Video that go into depth: June 10, 2024 - "15 minutes with Dr.Makis" - Episode 018: High Dose IVERMECTIN and CANCER 2024 - NEW STUDIES 2024 Baghli et al - Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular Protocol First-in-the-World Ivermectin, Mebendazole and Fenbendazole Protocol in Cancer has been peer-reviewed and published on Sep.19, 2024. Co-authors include Dr Paul Marik and Dr William Makis. 2024 Fan et al - Ivermectin Inhibits Bladder Cancer Cell Growth and Induces Oxidative Stress and DNA Damage ( 2024 Man-Yuan Li et al ) - Ivermectin induces non-protective autophagy by downregulating PAK1 and apoptosis in lung adenocarcinoma cells ( 2024 Kaur et al ) - Ivermectin: A Multifaceted drug with a potential beyond anti-parasitic therapy ( 2024 Xing Hu et ...
If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories . We have seen tremendous demand for some sort of guide on how to use fenbendazole for cancer as there is also tremendous confusion both from the healthcare and non-healthcare communities. Joe Tippens founded the protocol (1) after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mice. The scientist was later diagnosed with ...
We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. According to oncologist Dr William Makis: “ This paper is the FIR...
Contents: Editor's Preface Introduction Fenbendazole Case Series Compilation (alphabetical) Appendix Cancer Breast Cancer Success Stories (11 cases) Brain Cancer (Glioblastoma) Bile Duct Cancer (Cholangiocarcinoma) Bladder Cancer Success Stories (5 cases) Cervical Cancer Colorectal Cancer (11 cases) Esophageal and Stomach cancer Endometrial Cancer (4 cases) Gastric (Stomach) cancer (3 cases) Head and Neck Cancer (3 cases) Kidney Cancer Case Series (8 cases) Liver Cancer (2 cases) Lung Cancer (11 cases) Leukemia (2 cases) Lymphoma (4 cases) Melanoma (Skin Cancer) Multiple Myeloma Myelodysplastic Syndrome Oral Cancer Ovarian Cancer (2 cases) Pancreatic Cancer (9 cases) Prostate Cancer (15 cases) Salivary Gland Cancer Sarcoma (2 cases) Skin ...
Readers ask a variety of questions regarding the use of fenbendazole. This article is mainly a result of those questions and has been in the hopper for quite a while. It is long overdue as it contains items of importance that, if we waited for the appropriate thematic venue to publish them, they might never see the light of day. With that in mind, please accept the following for what it is: a hodgepodge of fenbendazole-related items that are very important to know. Incorporate these bits and pieces into your arsenal of ideas regarding fenbendazole, any unique insights that come to mind please feel free to share. How Safe is Fenbendazole? Is fenbendazole harmful to humans? Due to the long and successful use of fenbendazole as a veterinary antiparasitic medicine since the late 1950s, a wealth of safety data has been acquired that has stood the test of time. According to Drugs.com, there are no commonly used drugs that interact with fenbendazole. Fenbendazole is so safe for veterina...
What is fenbendazole used for in humans? Fenbendazole (also known as fenben) is a veterinary medication used to treat parasites and worms such as tapeworms, hookworms, roundworms, and whipworms, in animals. It is commonly used under brand names like Panacur C and Safe-Guard. If you have been diagnosed with cancer, or have a loved one that is suffering from cancer, chances are you have heard about the Joe Tippens Cancer Protocol. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories. Joe Tippens founded the protocol after he was told a story about a scientist at Merck Animal Health that had been performing cancer research on mice. The research included injecting different types of cancers into different mice body parts. The scientists discovered, through trial and error, a product in their canine product line, fenbendazole, that was batting 1.000 in killing these different cancers in the mic...
Transcription (emphasis 2SG - 2nd Smartest Guy): Hi, everyone. Welcome to another episode of 15 minutes with Dr. Makis, my new hard hitting medical podcast. This episode is about fenbendazole and cancer. I will give you the most comprehensive review of the use of fenbendazole in cancer there is. Fenbendazole is an antiparasitic. It is a dog dewormer, has been used It's been used as an antiparasitic since the 1960s, and it has been shown to have extensive anti cancer activity. Now, it's not FDA approved for use in humans. There is a version of it that is almost identical that is approved for use in humans by the FDA, and it's called mebendazole. (2SG: Mebendazole is BigPharma’s money grab whereby they removed a molecule from fenbendazole such that they could egregiously up-charge for a slightly inferior compound based on a bogus patent). I will do a separate video for mebe...
Fenbendazole is a broad spectrum anthelmintic used against gastrointestinal parasites including: giardia, roundworms, hookworms, whipworms, the tapeworm genus Taenia (but not effective against Dipylidium caninum, a common dog tapeworm), pinworms, aelurostrongylus, paragonimiasis, strongyles, and strongyloides that can be administered to sheep, cattle, horses, fish, dogs, cats, rabbits, most reptiles, freshwater shrimp tanks as planaria and hydra treatments, as well as seals. One such study found unexpected tumor growth inhibition in a group of mice treated with a combination of Fenbendazole and vitamins. As more studies emerge – some already published, some currently ongoing – a rapidly growing number of human patients are taking Fenbendazole to treat their cancer. The Fenbendazole Cancer Protocol has been gaining rapid interest over the past years following some fenbendazole advanced cancer success stories. Joe Tippens founded the protocol after he was told a story about a s...
The latest weight loss craze to hit Hollywood and beyond is semaglutide, more popularly known as Ozempic, the brand name of the drug marketed to improve blood sugar in people with Type 2 diabetes. Semaglutide is also known as Wegovy, which is prescribed to adults interested in weight loss. The weekly injectable drug is available only by prescription — and costs $1,349 a month (1) — but it’s in high demand among those looking to shed a few pounds. Note: Semaglutide is known by the brand names Ozempic, Wegovy, Rybelsus and others. New York dermatologist Dr. Paul Jarrod Frank told People, "It's the drug of choice these days for the 1%."(2) He says he can always spot users due to "Ozempic face," a gaunt appearance that can occur due to fat loss, which may make you appear older, particularly in the face. But this undesirable side effect is the least of your worries if you choose to use semaglutide. The blockbuster drug, slated to bring in more than $10 billion in ann...
Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses. Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to cancer type and stage. Ivermectin dosage should be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. Cancer dosage estimation can be adjusted based on the time that a person has to beat cancer or its risk to the patient - this includes both the cancer type and whether the ca...
Comments
Post a Comment